Gelonghui, April 30 | Linuotebo (301188.SZ) announced that the company's borosilicate glass molded injection bottle recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as “CDE”), and the registration number has changed to “A” status on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information disclosure platform.
The company's borosilicate glass molded injection bottles indicate that the borosilicate glass molded injection bottles produced by the company can be officially sold in batches after the relevant formulations are approved (converted to “A” status).
This time, the company's borosilicate glass molded injection bottles have changed to an “A” status, which responds to the national consistency evaluation policy, can better meet the growing demand of downstream customers for borosilicate molded bottles, further expand the company's market share in the pharmaceutical packaging field, and contribute to the company's business performance, which is conducive to the achievement of the company's strategic goals.